Ascendis Pharma A/S annual return on equity
2016
2017
2018
2019
2020
2021
2022
2023
Ascendis Pharma A/S Return on Equity (ROE) Growth & History (ASND)
Ascendis Pharma A/S's return on equity was −818.43% for fiscal 2023.
View full Ascendis Pharma A/S company overviewAscendis Pharma A/S annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −818.43% | −716.74 pp |
| 2022 | 2022-12-31 | −101.69% | −57.15 pp |
| 2021 | 2021-12-31 | −44.54% | +13.82 pp |
| 2020 | 2020-12-31 | −58.36% | −8.65 pp |
| 2019 | 2019-12-31 | −49.71% | +5.98 pp |
| 2018 | 2018-12-31 | −55.68% | +12.42 pp |
| 2017 | 2017-12-31 | −68.11% | −21.97 pp |
| 2016 | 2016-12-31 | −46.14% | — |
Ascendis Pharma A/S quarterly return on equity
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.51% | — |
| Q1 2026 | 2026-03-31 | 387.10% | — |
| Q2 2023 | 2023-06-30 | −104.66% | −91.97 pp |
| Q1 2023 | 2023-03-31 | −51.52% | −35.40 pp |
| Q4 2022 | 2022-12-31 | −58.03% | −46.73 pp |
| Q3 2022 | 2022-09-30 | −31.90% | −22.34 pp |
| Q2 2022 | 2022-06-30 | −12.70% | +5.33 pp |
| Q1 2022 | 2022-03-31 | −16.13% | −8.48 pp |
| Q4 2021 | 2021-12-31 | −11.30% | +4.22 pp |
| Q3 2021 | 2021-09-30 | −9.56% | +7.48 pp |
| Q2 2021 | 2021-06-30 | −18.03% | +0.47 pp |
| Q1 2021 | 2021-03-31 | −7.65% | +3.40 pp |
| Q4 2020 | 2020-12-31 | −15.52% | −2.75 pp |
| Q3 2020 | 2020-09-30 | −17.04% | −13.28 pp |
| Q2 2020 | 2020-06-30 | −18.51% | −10.04 pp |
| Q1 2020 | 2020-03-31 | −11.05% | −0.29 pp |
| Q4 2019 | 2019-12-31 | −12.78% | −1.83 pp |
| Q3 2019 | 2019-09-30 | −3.76% | +6.91 pp |
| Q2 2019 | 2019-06-30 | −8.46% | −1.76 pp |
| Q1 2019 | 2019-03-31 | −10.76% | +4.72 pp |
| Q4 2018 | 2018-12-31 | −10.95% | +7.84 pp |
| Q3 2018 | 2018-09-30 | −10.67% | — |
| Q2 2018 | 2018-06-30 | −6.70% | — |
| Q1 2018 | 2018-03-31 | −15.48% | — |
| Q4 2017 | 2017-12-31 | −18.79% | — |
Ascendis Pharma A/S return on equity trends
Over the last five fiscal years, Ascendis Pharma A/S's return on equity decreased from −55.68% to −818.43%, a change of −762.75 percentage points. The latest reported quarter, Q2 2026, shows 21.51%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ascendis Pharma A/S source filings ↗